Background
==========

Exercise capacity is the most common measure of cardiovascular and metabolic efficiency. The six minute walk test (6MWT) is a standard procedure used to evaluate exercise capacity in pulmonary and cardiac patients \[[@B1]\]. Although the cardiopulmonary exercise test with gas exchange is the "gold standard" method for measuring exercise in respiratory medicine, its use in routine clinical practice is limited because it requires expensive and complex technology. The 6MWT is the most widely used because it is both simple and reliable as a measure of exercise capacity.

The 6MWT is internationally used to measure functional status and prognosis in patients with a wide variety of diseases, such as pulmonary hypertension, congestive heart failure or chronic obstructive pulmonary disease (COPD). It can also be utilized to investigate the effects of several interventions (rehabilitation, pharmacological therapy, oxygen supplementation) on the patients' walking capacity \[[@B2],[@B3]\]. This test, referred to as a sub-maximal high-intensity constant-load exercise, is conducted for a period of 6 minutes while the patient is walking as far as possible. A supervised measurement of the distance walked (in meters), with associated pulse oximetry evaluations, and rating of dyspnea detected with the Borg scale or with visual analogic scale are then recorded as outcome measures \[[@B3]\]. In COPD patients the distance walked correlates moderately with either an individual's health-related quality of life, symptoms, peak work capacity as assessed by CPET or pulmonary function \[[@B2],[@B3]\]. Most important, the distance walked is a surrogate marker of long-term survival in COPD patients, even when they are in the most advanced status of their disease \[[@B3]\].

Many patients with chronic respiratory diseases, particularly those with COPD present a dysfunction related to a disorder of the skeletal muscles that reflects a limitation in exercise capacity \[[@B3]\]. COPD is a pulmonary disorder that is characterized by progressive irreversible airflow limitation resulting from alveolar wall destruction, bronchiolar narrowing, and airways inflammation \[[@B4]\]. Individuals with COPD usually show a limited capacity to perform exercise. When compared to healthy individuals they demonstrate lower maximum exercise capacities with the lowest levels observed in subjects with more severe COPD \[[@B5]\]. Patients with COPD typically experience dyspnea during exercise and stop exercising because of dyspnea or leg fatigue or a combination of both. Patients with mild COPD usually perceive dyspnea more intensely than leg fatigue \[[@B6],[@B7]\]. In this group the breathing pattern is more rapid and shallow and is the cause of dynamic hyperinflation which generates an inspiratory threshold due to positive end-expiratory pressure which results in a reduction of inspiratory capacity strictly related to dyspnea and in respiratory effort \[[@B7]\]. Dynamic hyperinflation is the result of expiratory flow limitation: most people with COPD are able to maintain a stable end expiratory lung volume (EELV) and inspiratory capacity (IC) at rest. However, with the increased ventilatory demand imposed by exercise, the expiratory flow limitation arise. This leads to increased EELV and reduced IC.These two parameters have been identified as major contributory factors to dispnea in COPD patients \[[@B8]\].Treatments to reduce airflow obstruction and/or dynamic hyperinflation include pursed lip breathing (PLB) \[[@B9]\], several non-pharmacological therapies that include supplemental oxygen, heliox, breathing helium-oxygen mixtures, and non-invasive ventilation \[[@B7],[@B9]\]. There is evidence that non-invasive ventilation reduces the work of breathing during exercise which in turn decreases dyspnea and increases endurance time in patients with moderate to severe COPD. Several studies have demonstrated a relationship between decreased dyspnea and reduced work of breathing \[[@B7],[@B10]-[@B12]\]. Only few evidences exist concerning the use of positive expiratory devices: these devices should permit a reduction in lung hyperinflation and an increasing in exercise duration (endurance) \[[@B13]\]. On this regard we decided to investigate if the use of a positive expiratory pressure device could improve the distance walked by patients with moderate to severe COPD.

Methods
=======

Patients and study design
-------------------------

A prospective, randomized controlled trial was performed from April 2012 to September 2012 in consecutive in-and outpatients with moderate to severe COPD recruited at the Respiratory Diseases Unit of the General Hospital of Sestri Levante (GE, Italy). Inclusion criteria were: age from 18 to 80 years, and clinical stability (no change in medication within a week prior to the test). Exclusion criteria were: history of bronchial asthma, inability to perform the six minute walk test, or absence of written consent.

A randomization plan was generated by a statistician not involved in the study using a randomization table from a computer software program. The randomization assignments were provided to the recruiting physician in sealed envelopes. The investigators who performed the study's data analysis were blinded to the patients' assignments.

The study was carried out in accordance with the Helsinki Declaration. All patients provided written informed consent before beginning the study. The study was registered as Chi CTR-ORC-12002173 at <http://www.chictr.org>.

Protocol
--------

We assessed the effects of a positive expiratory pressure (PEP) device during 6MWT in patients with moderate to severe COPD.

137 patients were enrolled in the study and 100 were randomized (37 were excluded: 27 refused informed consent and 10 were unable to perform 6MWT). The demographic and baseline characteristics of the enrolled patients are reported in Table  [1](#T1){ref-type="table"}. The patients' flow chart is reported in Figure [1](#F1){ref-type="fig"}. Pulmonary function testing was performed with a computerized body plethysmograph (VMAX 20 PFT Sensor Medics, Yorba Linda, CA,US), according to the international standards \[[@B14]\].

###### 

**Patients**' **characteristics at baseline**

                **PEP Group n** = **50 patients**   **Control group n** = **50 patients**
  ------------ ----------------------------------- ---------------------------------------
  GENDER F/M                  24/50                                 18/50
  AGE years                71.9 ± 4.0                            72.1 ± 4.1
  FVC%                    51.26 ± 11.89                         49.67 ± 12.68
  FEV1%                   35.14 ± 14.56                         33.48 ± 10.57
  FEV1/FVC%                48.2 ± 8.4                            53.2 ± 5.5
  TLC%                   147.36 ± 44.29                        129.44 ± 10.27
  RV%                     148.82 ± 13.4                        140.88 ± .13.22
  DLCO%                   54.68 ± 11.40                         60.03 ± 0.10
  paO2                     67.1 ± 6.6                            61.8 ± 7.0
  paCO2                    44.7 ± 3,3                            43.8 ± 5.0
  pH                       7.41 ± 0,1                            7.42 ± 0,2

DL~CO~, Lung diffusing capacity for carbon monoxide; FEV~1,~ Forced expiratory volume 1 sec; FEV~1~/FVC Tiffeneau index; FVC, Forced vital capacity; PaCO~2~, carbon dioxide arterial pressure. PaO~2~, oxygen arterial pressure; PEP, Positive Expiratory Pressure;RV, Residual volume; TLC, Total lung capacity.

![**Patients**' **flow.**](2049-6958-8-19-1){#F1}

Each patient underwent 6MWT in the first day, the test was performed twice to avoid learning effect \[[@B15]\]; the test of the two (performed the same day and separated each other by at least 30 minutes) with the longest covered distance was inserted in data analysis \[[@B15]-[@B17]\]. The following day the subjects were randomized to the PEP arm (50 patients) or to the Control arm (50 patients). PEP group patients repeated 6MWT only once using a PEP device consisting in a Respironics Threshold PEP valve set at 5cmH~2~O \[[@B18]\] connected to a 20 mm inner diameter and 100 mm tube and a mouthpiece (Figures  [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}) \[[@B19]\]. Control group patients repeated 6MWT only once breathing without this device. A different chest physiotherapist performed the 6MWT and he/she was blinded about the results of the previous test. 6MWT was performed according to the American Thoracic Society guidelines \[[@B20]\].

![**Positive expiratory pressure(PEP)device used for 6 MWT composed by a 5 cm H2O Respironics PEP**-**valve**,**a tube and a mouthpiece.**](2049-6958-8-19-2){#F2}

![A participant using PEP device before 6 MWT.](2049-6958-8-19-3){#F3}

Oxygen saturation, heart rate, respiratory rate, dyspnea (using the Borg scale), and distance walked (meters) were recorded at the beginning and the end of every test as previously indicated \[[@B13]\]. A lightweight bluetooth wireless oxymeterNonin Avant 4000 was used for continuous oxygen saturation and heart rate measurements.

Data analysis and statistics
----------------------------

Primary outcome was the difference in distance (meters) walked between the test before enrollment and the test after enrollment. Secondary outcomes were the differences in oxygen saturation, the reduction in dyspnea (Borg scale), and in respiratory rate. Descriptive data for continuous variables with a normal distribution are presented as mean ± standard deviation. Covariance analysis was used for assessing the difference between 6MWT with or without PEP. Multivariate analysis was used to evaluate correlations between cardio-pulmonary function parameters and patient performance. The effects of possible confounding factors (sex, age, meters walked on the first test) were determined by introducing these variables in the final model and calculating the change in the predictive factors coefficients.

Data analysis was done with statistics software R-Project version 7.13.2. A significance level of p \< 0.05 was used for all comparisons.

Results
=======

All one hundred patients concluded the study. There were twenty-four females in the PEP group and eighteen in the control group. The average age of the participants was 71.9 ± 4.0 in the PEP group and 72.1 ± 4.1 in control group. 36 patients of the PEP group were being treated with association of inhaled β~2~ agonist plus corticosteroid and tiotropium bromide; the remaining 14 with β~2~ agonist and tiotropium. 39 patients of the PEP group were being treated with association of β~2~ agonist plus corticosteroid and tiotropium bromide; the remaining 11 with β~2~ agonist and tiotropium bromide. 3 patients of the PEP group and 4 patients of the control group had chronic respiratory insufficiency treated with oxygen.

All patients had similar reduction in lung volumes (FVC % 51.26 ± 11.89 in PEP group and 49.67 ± 12.68 in control group, FEV~1~% 35.14 ± 14.56 in PEP group and 33.48 ± 10.57 in control group). The 6MWT at baseline was 232.56 ± 101.59 in PEP group and 262.44 ± 95.02 in control group.

Primary outcomes
----------------

Functional capacity assessed by the distance covered during 6 MWT improved in PEP group more than in the control group. The PEP group showed an increase in meters walked (61.66 ± 4.28) versus Control group (3.23 ± 0.59). The difference was statistically significant (p \< 0.001). The mean values of distances walked and p-values are reported in Figure [4](#F4){ref-type="fig"}.

![Trend analysis of distance (T0--T1) (meters walked) in the PEP group and in the Control group (p \< 0.001).](2049-6958-8-19-4){#F4}

Secondary outcomes
------------------

Oxygen saturation improved to a statistically significant level during 6 MWT (p \< 0.01). Heart rate was reduced (p \< 0.03). Also dyspnea (Borg scale) and the respiratory rate showed a reduction in the PEP group, but these did not achieve statistical significance. All results are showed in Table  [2](#T2){ref-type="table"}. The patients showing ability to maintain an adequate level of saturation improved the distance walked (multivariate analysis) (p \< 0.03).

###### 

Results of parameters evaluated before and after 6MWT in the two groups of patients (PEP group--Control group)

                                  **6MWT 1**^st^**TEST**   **6MWT 2**^nd^**TEST**                                    
  ------------------------------ ------------------------ ------------------------ ---------------- ---------------- ---------
                                      Group A (PEP)               Group B           Group A (PEP)       Group B         *p*
  **Distance walked (meters)**                                                                                            
                                     232.56 ± 101.59           262.44 ± 95.02       294.22 ± 97.31   265.67 ± 94.43   \< 0.02
  **Dyspnea (Borg)**                                                                                                      
   Time 0\*                            1.63 ± 1.20              1.08 ± 1.03          1.49 ± 0.90      0.86 ± 0.97     0.4339
   Time 1\*\*                          4.29 ± 1.75              4.22 ± 2.01          3.18 ± 1.65      4.41 ± 2.14         
  **Respiratory rate**                                                                                                    
   Time 0\*                            19.92 ± 5.26             20.68 ± 4.80         19.62 ± 4.64     20.65 ± 4.45    0.4884
   Time 1\*\*                          26.68 ± 4.04             27.08 ± 4.35         23.38 ± 5.09     27.22 ± 3.28        
  **Heart rate**                                                                                                          
   Time 0\*                           80.17 ± 14.70            78.75 ± 10.23        80.17 ± 12.72    76.67 ± 13.48    \<0.03
   Time 1\*\*                         96.66 ± 15.76            97.36 ± 11.71        92.56 ± 12.57    98.96 ± 13.86        
  **Oxygen saturation %**                                                                                                 
   Time 0\*                            94.74 ± 0.01             94.61 ± 0.01         94.96 ± 0.02     94.84 ± 0.01    \<0.01
   Time 1\*\*                          88.97 ± 0.04             90.27 ± 0.04         90.75 ± 0.03     89.76 ± 0.04        

\* At the beginning of the test.

\*\* At the end of the test.

Discussion
==========

The present study suggests that adding a low positive pressure (5 cmH~2~O) PEP device enhances exercise capacity expressed as distance walked during 6MWT in patients with moderate to severe COPD. The principal effect of PEP device consists in increasing expiratory flow and decreasing pulmonary hyperinflation during exercise.

Expiratory flow limitation, which is the primary pathophysiological hallmark of chronic obstructive, is caused by reduced lung elastic recoil and increased airway resistance. Forced expiration associated with increased ventilatory demands during exercise can induce premature airway closure leading to air trapping and dynamic hyperinflation \[[@B13]\]. Dynamic hyperinflation contributes to increased elastic and mechanical loads on the inspiratory muscles and to neuroventilatory dissociation which further exacerbate the shortness of breath, leading to exercise intolerance, limited physical activity and thus to a poor quality of life \[[@B21]\]. Exercise tolerance is an important outcome measure in patients with COPD, because there is evidence that exercise testing is superior to other functional measurements obtained at rest in demonstrating the positive effect of a specific intervention. Some drugs such as formoterol and tiotropium demonstrate ability to change exercise tolerance and 6 MWT \[[@B22],[@B23]\]. Non-invasive ventilation was used to improve exercise tolerance in COPD patients \[[@B24]-[@B27]\]. One of the various explored strategies to manage dynamic hyperinflation is to increase expiratory time as a result of slowing the respiratory rate by using low-level positive expiratory pressure \[[@B28]\]. Positive expiratory pressure devices can prolong expiratory time and decrease respiratory rate, thereby reducing airway closure and dynamic hyperinflation. The use of an expiratory positive airway pressure (associated with incentive spirometry) was described in a study in patients after coronary artery bypass graft. The application of a positive expiratory pressure improved the distance walked in 6MWT compared to controls \[[@B29]\]. The expiratory positive expiratory positive airway pressure promotes collateral ventilation, prevents airway collapse during expiration and thus reduces air trapping \[[@B29],[@B30]\].

Another study about the use of an expiratory positive pressure device in COPD patients showed that the use of a conical-PEP produced an increase in inspiratory capacity of 200 ml, slowdown in vital capacity, and lung hyperinflation, and the improvement of the exercise endurance \[[@B13]\]. Martin and Davenport in a double blind crossover study showed that an extrinsic 10 cmH~2~O threshold PEEP reduced post-exercises dyspnea in COPD patients \[[@B9]\]. Finally, Monteiro and others published in 2012 a study similar to the our in which the demonstrated an increase in inspiratory capacity in patients with moderate to severe COPD treated with PEP applied trough oronasal mask after submaximal treadmill exercise \[[@B31]\].

However our study presents an important limitation: we did not measure the dynamic hyperinflation, and this is an important lack because a strict correlation exists between exercise dynamic hyperinflation, inspiratory capacity, dyspnea and exercise performance during 6MWT \[[@B32]\].

Conclusions
===========

Activity in COPD patients is limited by the development of dynamic hyperinflation. Changes in respiratory mechanics during exercise in patients with dynamic hyperinflation lead to exercise intolerance. The use of PEP during submaximal exercise may promote a reduction in the development of dynamic hyperinflation in COPD patients \[[@B31]\]. Our results has been obtained using only a low positive expiratory pressure (5 cm H~2~O) (the same obtained by pursed lips breathing) \[[@B13],[@B18]\] without an inspiratory support or an inspiratory incentive device. In our opinion the strength of our study is the simplicity and the minor cost when compared to other devices and approaches (such as non-invasive ventilation or incentive spirometry with expiratory positive airway pressure or even conical-PEP). The use of PEP devices in rehabilitation programs is well known \[[@B9]\]: future studies would be needed to verify the usefulness of this device in the usual way (daily activity) during training and reconditioning.
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